Logo image of LVTX

LAVA Therapeutics NV (LVTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LVTX - NL0015000AG6 - Common Stock

1.74 USD
-0.07 (-3.87%)
Last: 11/20/2025, 8:00:00 PM
Fundamental Rating

3

Overall LVTX gets a fundamental rating of 3 out of 10. We evaluated LVTX against 530 industry peers in the Biotechnology industry. LVTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, LVTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LVTX had negative earnings in the past year.
LVTX had negative earnings in each of the past 5 years.
LVTX had negative operating cash flow in 4 of the past 5 years.
LVTX Yearly Net Income VS EBIT VS OCF VS FCFLVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

LVTX has a Return On Assets of -69.12%. This is in the lower half of the industry: LVTX underperforms 61.68% of its industry peers.
LVTX has a Return On Equity of -190.76%. This is in the lower half of the industry: LVTX underperforms 68.22% of its industry peers.
Industry RankSector Rank
ROA -69.12%
ROE -190.76%
ROIC N/A
ROA(3y)-31.44%
ROA(5y)-40.51%
ROE(3y)-69.63%
ROE(5y)-90.26%
ROIC(3y)N/A
ROIC(5y)N/A
LVTX Yearly ROA, ROE, ROICLVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 100.00%, LVTX belongs to the top of the industry, outperforming 99.07% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for LVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LVTX Yearly Profit, Operating, Gross MarginsLVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

LVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LVTX remains at a similar level compared to 1 year ago.
Compared to 5 years ago, LVTX has more shares outstanding
The debt/assets ratio for LVTX is higher compared to a year ago.
LVTX Yearly Shares OutstandingLVTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
LVTX Yearly Total Debt VS Total AssetsLVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

LVTX has an Altman-Z score of -4.42. This is a bad value and indicates that LVTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.42, LVTX is not doing good in the industry: 60.56% of the companies in the same industry are doing better.
LVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.42
ROIC/WACCN/A
WACC7.09%
LVTX Yearly LT Debt VS Equity VS FCFLVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 6.73 indicates that LVTX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.73, LVTX is in the better half of the industry, outperforming 68.41% of the companies in the same industry.
LVTX has a Quick Ratio of 6.73. This indicates that LVTX is financially healthy and has no problem in meeting its short term obligations.
LVTX has a better Quick ratio (6.73) than 68.60% of its industry peers.
Industry RankSector Rank
Current Ratio 6.73
Quick Ratio 6.73
LVTX Yearly Current Assets VS Current LiabilitesLVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.50% over the past year.
Looking at the last year, LVTX shows a very strong growth in Revenue. The Revenue has grown by 77.01%.
The Revenue has been growing by 33.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.3%
Revenue 1Y (TTM)77.01%
Revenue growth 3Y33.82%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LVTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.53% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y7.87%
EPS Next 2Y20.48%
EPS Next 3Y16.82%
EPS Next 5Y11.53%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LVTX Yearly Revenue VS EstimatesLVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 5M 10M 15M
LVTX Yearly EPS VS EstimatesLVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LVTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LVTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LVTX Price Earnings VS Forward Price EarningsLVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LVTX Per share dataLVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

LVTX's earnings are expected to grow with 16.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.48%
EPS Next 3Y16.82%

More info and screens

0

5. Dividend

5.1 Amount

LVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LAVA Therapeutics NV

NASDAQ:LVTX (11/20/2025, 8:00:00 PM)

1.74

-0.07 (-3.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-26 2026-03-26/amc
Inst Owners27.59%
Inst Owner Change27.6%
Ins Owners0.73%
Ins Owner Change-69.19%
Market Cap45.78M
Revenue(TTM)11.98M
Net Income(TTM)-49.19M
Analysts45.71
Price Target1.4 (-19.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.08%
Min EPS beat(2)53.47%
Max EPS beat(2)66.68%
EPS beat(4)3
Avg EPS beat(4)24.77%
Min EPS beat(4)-36.66%
Max EPS beat(4)66.68%
EPS beat(8)6
Avg EPS beat(8)15.96%
EPS beat(12)10
Avg EPS beat(12)26.68%
EPS beat(16)14
Avg EPS beat(16)24.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)6.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.82
P/FCF N/A
P/OCF N/A
P/B 1.78
P/tB 1.78
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.46
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.12%
ROE -190.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-31.44%
ROA(5y)-40.51%
ROE(3y)-69.63%
ROE(5y)-90.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.73
Quick Ratio 6.73
Altman-Z -4.42
F-ScoreN/A
WACC7.09%
ROIC/WACCN/A
Cap/Depr(3y)66.67%
Cap/Depr(5y)88.88%
Cap/Sales(3y)4.68%
Cap/Sales(5y)8.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.3%
EPS Next Y7.87%
EPS Next 2Y20.48%
EPS Next 3Y16.82%
EPS Next 5Y11.53%
Revenue 1Y (TTM)77.01%
Revenue growth 3Y33.82%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-82.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.48%
OCF growth 3YN/A
OCF growth 5YN/A

LAVA Therapeutics NV / LVTX FAQ

What is the fundamental rating for LVTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to LVTX.


What is the valuation status of LAVA Therapeutics NV (LVTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to LAVA Therapeutics NV (LVTX). This can be considered as Overvalued.


How profitable is LAVA Therapeutics NV (LVTX) stock?

LAVA Therapeutics NV (LVTX) has a profitability rating of 1 / 10.


Can you provide the financial health for LVTX stock?

The financial health rating of LAVA Therapeutics NV (LVTX) is 6 / 10.


Can you provide the expected EPS growth for LVTX stock?

The Earnings per Share (EPS) of LAVA Therapeutics NV (LVTX) is expected to grow by 7.87% in the next year.